诺思兰德(430047) - 2022 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss for the reporting period, estimated between -72 million to -60 million CNY, compared to a net loss of -51.57 million CNY in the same period last year[2] - The primary reason for the significant loss is the ongoing research and development of biopharmaceuticals, which has not yet resulted in product sales, despite an increase in revenue from ophthalmic drugs[3] - The financial data provided is preliminary and has not been audited by an accounting firm, emphasizing the need for investors to be cautious[4]